PTEN and TP53 mutations were not associated with decreased survival rate when looking at the entire cohort; however, histological-specific identification of mutations of PTEN or TP53 in RCC subtypes was associated with poor survival. This evidence concerns the gene TP53 and renal cell carcinoma.